Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JNXDB
ADC Name
XMT-1592
Synonyms
XMT 1592;XMT1592; XMT-1592
   Click to Show/Hide
Organization
Mersana Therapeutics, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 2 Indication(s)
Lung cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
6
Structure
Antibody Name
Undisclosed
Antigen Name
Sodium-dependent phosphate transport protein 2B (SLC34A2)
  Antigen Info 
Payload Name
Auristatin F hydroxypropylamide (AF-HPA)
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Cys-13 ADC linker
  Linker Info 
Conjugate Type
Enzymatic Catalysis
Puchem SID
474492406
DrugMap ID
DMU6TG7
TTD ID
DDL79K
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04396340
Phase 1/2
A phase 1b, first-in-human, dose escalation and expansion study of XMT-1592 in patients with solid tumors likely to express NAPI2B.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04396340  Clinical Status Phase 1/2
Clinical Description A phase 1b, first-in-human, dose escalation and expansion study of XMT-1592 in patients with solid tumors likely to express NAPI2B.
References
Ref 1 A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b, NCT04396340